462 related articles for article (PubMed ID: 26147597)
1. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Wei YQ; Wang DG; Yang H; Cao H
PLoS One; 2015; 10(7):e0132561. PubMed ID: 26147597
[TBL] [Abstract][Full Text] [Related]
2. [The effects of cytochrome P450 2C19 genetic polymorphism on clopidogrel resistance and recent prognosis of patients with acute coronary syndrome].
Li SN; Liu Z; Luo Y; Chen PA; Lei XM; Li GL
Zhonghua Nei Ke Za Zhi; 2013 Nov; 52(11):961-5. PubMed ID: 24439192
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
[TBL] [Abstract][Full Text] [Related]
4. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
[TBL] [Abstract][Full Text] [Related]
5. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
[TBL] [Abstract][Full Text] [Related]
6. Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents.
Ichikawa M; Takei Y; Hamasaki T; Kijima Y
Circ J; 2015; 79(1):85-90. PubMed ID: 25744629
[TBL] [Abstract][Full Text] [Related]
7. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
Arima Y; Hokimoto S; Akasaka T; Mizobe K; Kaikita K; Oniki K; Nakagawa K; Ogawa H
J Cardiol; 2015 Jun; 65(6):494-500. PubMed ID: 25156215
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of clopidogrel.
O'Connor SA; Hulot JS; Silvain J; Cayla G; Montalescot G; Collet JP
Curr Pharm Des; 2012; 18(33):5309-27. PubMed ID: 22724417
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome.
Cuisset T; Quilici J; Cohen W; Fourcade L; Saut N; Pankert M; Gaborit B; Carrieri P; Morange PE; Bonnet JL; Alessi MC
Am J Cardiol; 2011 Sep; 108(6):760-5. PubMed ID: 21803320
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
[TBL] [Abstract][Full Text] [Related]
13. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
[TBL] [Abstract][Full Text] [Related]
14. [Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention].
Tang XF; He C; Yuan JQ; Meng XM; Yang YJ; Qin XW; Qiao SB; Liu HB; Wu YJ; Yao M; Chen J; You SJ; Wu Y; Li JJ; Dai J; Chen JL; Gao RL; Chen ZJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jul; 39(7):617-20. PubMed ID: 22088240
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
[TBL] [Abstract][Full Text] [Related]
16. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
[TBL] [Abstract][Full Text] [Related]
17. Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome.
Khalaf H; Al Meman AA; Rasool S
Drug Metab Lett; 2016; 10(1):65-70. PubMed ID: 26573281
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
Guo YM; Zhao ZC; Zhang L; Li HZ; Li Z; Sun HL
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323099
[TBL] [Abstract][Full Text] [Related]
19. [Effects of clopidogrel resistence and CYP2C19 genotype on the clinical prognosis of patients with acute coronary syndrome undergoing percutaneous coronary intervention].
He CB; Li Q; Ye YC; Zhao XL; Tu CC; Zeng Y
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):765-771. PubMed ID: 32957760
[No Abstract] [Full Text] [Related]
20. Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
Hokimoto S; Chitose T; Mizobe M; Akasaka T; Arima Y; Kaikita K; Iwashita S; Morita K; Miyazaki H; Oniki K; Matsui K; Nakagawa K; Ogawa H
Eur J Clin Pharmacol; 2014 Jun; 70(6):667-73. PubMed ID: 24763934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
